A study on biofilm production and antifungal drug resistance among Candida species from vulvovaginal and bloodstream infections

Figures & data

Figure 1 Biofilm formation by Candida species in BSIs and vaginal candidiasis.

Abbreviation: BSIs, bloodstream infections.

Table 1 Biofilm production in different species of Candida in BSI and VVC

Candida spp.	Biofilm producers
	BSI biofilm positive/total	%	VVC biofilm positive/total	%
C. albicans	8/15	10.8	21/66	20.6
C. haemulonii	4/4	5.4	-	-
C. krusei	16/19	21.6	1/1	0.9
C. tropicalis	24/27	32.4	18/23	17.6
C. glabrata	1/3	1.3	5/10	4.9
C. parapsilosis	2/6	2.7	0/2	-

Abbreviations: BSI, bloodstream infection; C. albicans, Candida albicans; C. glabrata, Candida glabrata; C. haemolunii, Candida haemolunii; C. krusei, Candida krusei; C. parapsilosis, Candida parapsilosis; C. tropicalis, Candida tropicalis; VVC, vulvovaginal candidiasis.

Figure 2 Comparison of biofilm formation in various Candida spp.

Abbreviations: C. albicans, Candida albicans; C. glabrata, Candida glabrata; C. haemolunii, Candida haemolunii; C. krusei, Candida krusei; C. parapsilosis, Candida parapsilosis; C. tropicalis, Candida tropicalis.

Figure 3 Antifungal susceptibility pattern of azoles in BSI.

Abbreviations: BSI, bloodstream infection; C. albicans, Candida albicans; C. glabrata, Candida glabrata; C. haemolunii, Candida haemolunii; C. krusei, Candida krusei; C. parapsilosis, Candida parapsilosis; C. tropicalis, Candida tropicalis.

Figure 4 Antifungal susceptibility pattern of azoles in VVC.

Abbreviations: C. albicans, Candida albicans; C. glabrata, Candida glabrata; C. tropicalis, Candida tropicalis; VVC, vulvovaginal candidiasis.